Clinical Trial Update: Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating minimal residual disease assessment by next-generation sequencing to minimize exposure in patients with chronic lymphocytic le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Venclexta (venetoclax)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Status: ACTIVE_NOT_RECRUITING